Johannesburg Stock Exchange Approves New Financial Instruments for Fortress Real Estate Investments Limited
The Johannesburg Stock Exchange (JSE) has granted approval for new financial instrument listings to Fortress Real Estate Investments Limited, a company incorporated in the Republic of South Africa. The new listings are part of Fortress's Domestic Medium Term Note Programme, which aims to raise R 20,000,000,000.00. The programme will issue two new bonds, FIFB31 and FIFB32, with a total nominal value of R 820,000,000.00. The bonds will have a floating interest rate, with FIFB31 maturing on May 21, 2028, and FIFB32 maturing on May 21, 2030.
Key Takeaways:
- The JSE has approved the listing of two new financial instruments, FIFB31 and FIFB32, under Fortress's Domestic Medium Term Note Programme.
- The total authorized programme size is R 20,000,000,000.00, with a total amount in issue excluding these new listings at R 10,042,000,000.00.
- The new bonds will have a floating interest rate, with FIFB31 maturing on May 21, 2028, and FIFB32 maturing on May 21, 2030.
- The bonds will be dematerialized in the Central Securities Depository and settled electronically in terms of JSE rules.
- Debt sponsor Nedbank Corporate and Investment Banking will facilitate the issuance of the new bonds.
Statistics:
- R 20,000,000,000.00: The total authorized programme size.
- R 10,042,000,000.00: The total amount in issue excluding the new listings.
- R 820,000,000.00: The total nominal value of the two new bonds (FIFB31 and FIFB32).
- 3-Month JIBAR: The benchmark interest rate used to determine the interest rate for the bonds.
- 119 bps and 134 bps: The interest rate margins for FIFB31 and FIFB32, respectively.
Sources:
- Johannesburg Stock Exchange (JSE) company announcement regarding Fortress Real Estate Investments Limited.
- Fortress Real Estate Investments Limited's Domestic Medium Term Note Programme documents.
- Debt sponsor Nedbank Corporate and Investment Banking's materials.
- Johannesburg Stock Exchange (JSE) rules and regulations.